Frontiers in Cross-Protective Vaccines

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4078

Special Issue Editors

Department of Veterinary Medicine, University Aldo Moro of Bari, Sp Casamassima Km 3, Valenzano, 70010 Bari, Italy
Interests: coronaviruses; viral enteritis; respiratory and genital diseases
Special Issues, Collections and Topics in MDPI journals
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA
Interests: blood parasite; transmission blocking vaccine; Babesia; Transfection; vector born diseases; ticks; genetic markers; vaccines
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,  

Inclusion of cross-protective antigens is usually considered desirable when developing vaccines against different pathogens of several species and may also be important from a public health perspective. In this Special Issue, we encourage our colleagues to search within the abundant data available from all “omics” and other resources towards identifying promising cross-reactive antigens for vaccine development. Such vaccines may include single or multiple cross-reactive antigens and may help to prevent unpredictable homologous and heterologous infections. It is expected that this novel vaccine development approach will have a major impact in the context of disease prevention, while also having economic and practical advantages. We welcome your interesting research or review article covering these topics in our current Special Issue titled “Frontiers in Cross-Protective Vaccines”.

Prof. Dr. Maria Tempesta
Dr. Heba Alzan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • conserved epitope
  • cross protection
  • vaccine
  • heterogenicity
  • homology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 872 KiB  
Review
Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis
by Reginaldo G. Bastos, Heba F. Alzan, Vignesh A. Rathinasamy, Brian M. Cooke, Odir A. Dellagostin, Raúl G. Barletta and Carlos E. Suarez
Vaccines 2022, 10(1), 123; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10010123 - 14 Jan 2022
Cited by 4 | Viewed by 3285
Abstract
Babesiosis is a disease caused by tickborne hemoprotozoan apicomplexan parasites of the genus Babesia that negatively impacts public health and food security worldwide. Development of effective and sustainable vaccines against babesiosis is currently hindered in part by the absence of definitive host correlates [...] Read more.
Babesiosis is a disease caused by tickborne hemoprotozoan apicomplexan parasites of the genus Babesia that negatively impacts public health and food security worldwide. Development of effective and sustainable vaccines against babesiosis is currently hindered in part by the absence of definitive host correlates of protection. Despite that, studies in Babesia microti and Babesia bovis, major causative agents of human and bovine babesiosis, respectively, suggest that early activation of innate immune responses is crucial for vertebrates to survive acute infection. Trained immunity (TI) is defined as the development of memory in vertebrate innate immune cells, allowing more efficient responses to subsequent specific and non-specific challenges. Considering that Mycobacterium bovis bacillus Calmette-Guerin (BCG), a widely used anti-tuberculosis attenuated vaccine, induces strong TI pro-inflammatory responses, we hypothesize that BCG TI may protect vertebrates against acute babesiosis. This premise is supported by early investigations demonstrating that BCG inoculation protects mice against experimental B. microti infection and recent observations that BCG vaccination decreases the severity of malaria in children infected with Plasmodium falciparum, a Babesia-related parasite. We also discuss the potential use of TI in conjunction with recombinant BCG vaccines expressing Babesia immunogens. In conclusion, by concentrating on human and bovine babesiosis, herein we intend to raise awareness of BCG TI as a strategy to efficiently control Babesia infection. Full article
(This article belongs to the Special Issue Frontiers in Cross-Protective Vaccines)
Show Figures

Figure 1

Back to TopTop